Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
GDTC logo GDTC
Upturn stock ratingUpturn stock rating
GDTC logo

CytoMed Therapeutics Limited Ordinary Shares (GDTC)

Upturn stock ratingUpturn stock rating
$2
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: GDTC (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $5

1 Year Target Price $5

Analysts Price Target For last 52 week
$5 Target price
52w Low $1.2
Current$2
52w High $4.05

Analysis of Past Performance

Type Stock
Historic Profit -45.1%
Avg. Invested days 30
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 23.47M USD
Price to earnings Ratio -
1Y Target Price 5
Price to earnings Ratio -
1Y Target Price 5
Volume (30-day avg) 1
Beta -0.37
52 Weeks Range 1.20 - 4.05
Updated Date 08/29/2025
52 Weeks Range 1.20 - 4.05
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.17

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -530.32%

Management Effectiveness

Return on Assets (TTM) -17.44%
Return on Equity (TTM) -24.86%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 19961332
Price to Sales(TTM) 46.62
Enterprise Value 19961332
Price to Sales(TTM) 46.62
Enterprise Value to Revenue 369.21
Enterprise Value to EBITDA -4.45
Shares Outstanding 11733700
Shares Floating 3593787
Shares Outstanding 11733700
Shares Floating 3593787
Percent Insiders 68.86
Percent Institutions 0.43

ai summary icon Upturn AI SWOT

CytoMed Therapeutics Limited Ordinary Shares

stock logo

Company Overview

overview logo History and Background

CytoMed Therapeutics Limited is a Singapore-based biopharmaceutical company focused on the development of novel cell-based immunotherapies for the treatment of cancer. Founded in 2018, it leverages proprietary technologies to engineer and enhance natural killer (NK) cells and T cells for improved therapeutic efficacy. They primarily focus on advancing their pipeline of CAR-NK and TCR-T cell therapies.

business area logo Core Business Areas

  • Cell-Based Immunotherapies: Focuses on developing CAR-NK and TCR-T cell therapies for cancer treatment. This includes research, development, and clinical trials.
  • Proprietary Technologies: Developing and refining technologies for cell engineering and enhancement to improve therapeutic outcomes.

leadership logo Leadership and Structure

Dr. Tan Wee Kiat is the CEO. The organizational structure consists of research and development, clinical operations, and business development teams.

Top Products and Market Share

overview logo Key Offerings

  • CAR-NK Cell Therapy (CNK101): A cell-based immunotherapy targeting solid tumors. Currently in clinical trials. Market share is not yet applicable as the product is not yet approved. Competitors include Nkarta and Century Therapeutics
  • TCR-T Cell Therapy (CBT201): A cell-based immunotherapy targeting T cell lymphomas. Currently in preclinical development. Market share is not yet applicable as the product is not yet approved. Competitors include Atara Biotherapeutics.

Market Dynamics

industry overview logo Industry Overview

The cell-based immunotherapy market is rapidly growing, driven by advances in cancer treatment. It's characterized by high innovation, competition, and regulatory scrutiny.

Positioning

CytoMed is positioned as a company specializing in NK cell and T cell therapies, leveraging proprietary technologies to improve efficacy and safety. They are aiming to address unmet needs in solid tumors and hematological malignancies.

Total Addressable Market (TAM)

The global cell therapy market is projected to reach billions of USD. CytoMed aims to capture a segment of this market by developing innovative cell therapies for specific cancer indications.

Upturn SWOT Analysis

Strengths

  • Proprietary cell engineering technologies
  • Experienced leadership team
  • Focus on innovative cell therapies
  • Pipeline of CAR-NK and TCR-T cell therapies

Weaknesses

  • Limited financial resources compared to larger competitors
  • Early stage of clinical development
  • Reliance on successful clinical trial outcomes

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion into new therapeutic areas
  • Positive clinical trial results
  • Advancements in cell therapy technologies

Threats

  • Regulatory hurdles
  • Competition from established players
  • Clinical trial failures
  • Patent disputes

Competitors and Market Share

competitor logo Key Competitors

  • NKarta (NKTX)
  • Atara Biotherapeutics (ATRA)
  • Century Therapeutics (IPSC)

Competitive Landscape

CytoMed competes with other companies developing cell-based immunotherapies. Advantages include proprietary technologies and focus on specific cancer targets. Disadvantages include limited resources compared to larger competitors.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by expansion of R&D activities, preclinical studies, and initiation of clinical trials.

Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and potential partnerships. Analyst estimates will vary significantly based on the progress of their pipeline.

Recent Initiatives: Recent initiatives include advancing CNK101 in clinical trials and expanding the TCR-T cell therapy platform.

Summary

CytoMed Therapeutics Limited is a promising but still early-stage biopharmaceutical company focused on developing novel cell therapies. They possess proprietary technology and are working on a focused pipeline. Success hinges on positive clinical trial results and securing funding. They need to be aware of stiff competition and stringent regulatory requirements.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports
  • Press Releases

Disclaimers:

The information provided is for informational purposes only and should not be considered as financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About CytoMed Therapeutics Limited Ordinary Shares

Exchange NASDAQ
Headquaters -
IPO Launch date 2023-04-14
CEO -
Sector Healthcare
Industry Biotechnology
Full time employees 43
Full time employees 43

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company also has Business & Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.